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“ hat is time?” asked Saint Augustine in his
Confessions, “When someone asks me, I
know. But as soon as someone comes to
question me on this matter, and I try to
explain, I don’t know anymore.” A physician asked to deﬁne
an autoimmune disease has a similar sense of frustration.
For the perplexed, three features of autoimmune diseases,
derived from Witebsky’s postulates, might help: 1) the
presence of deﬁned autoantigens and autoantibodies; 2)
passive transfer of T-lymphocytes, which leads to disease
development; and 3) successful immunomodulation of
disease (1). Indeed, for type 1 diabetes in humans we
know that autoantibodies are common and, alas, also that
the second postulate is unethical and the third controver-
sial. In reality, a disease is considered autoimmune when
target organ destruction is allied to the presence of
disease-speciﬁc target organ autoantibodies (2). It is
through their clinical phenotype that diseases gain iden-
tity; only recently have we used genetic and immune
responses to adapt disease names. Therefore, the histori-
cal characteristic of severe diabetes as childhood-onset
disease was supplanted by insulin-dependent diabetes and
with identiﬁcation of diabetes-associated autoantibodies
and genetic susceptibility through the major histocompati-
bilty complex (MHC) for type 1 diabetes, or more precisely
type 1a diabetes, with type 2 diabetes being everything
type 1 diabetes was not (2,3).
From the earliest years it was apparent that childhood
diabetes was not always insulin dependent and vice versa.
A revised classiﬁcation of type 1 diabetes recognized as
much when it excluded the term insulin dependent,
thereby also excluding two features, ketoacidosis and
insulin therapy, which were previously regarded as cate-
gorical features of this disease (3). Further complexity
ensued with the recognition that a proportion of patients
with ketosis-prone diabetes can stop insulin therapy,
whereas 5–10% of adult-onset noninsulin-requiring dia-
betic patients have diabetes-associated autoantibodies
(4,5). Indeed, adult-onset autoimmune diabetes is only one
form of a broad spectrum of autoimmune diabetes,
whether viewed genetically, immunologically, metaboli-
cally, or clinically (Fig. 1). When viewed genetically, MHC
susceptibility, typical of autoimmune diabetes, is less
striking in adulthood (6). From the immunological per-
spective, autoimmune diabetes is characterized by auto-
antibodies, although their number in a given subject
declines with increasing age at onset (7). Metabolically,
insulin secretory loss, but not insensitivity, is less pro-
nounced in adulthood (8,9). From the clinical aspect,
noninsulin-requiring autoimmune diabetes is most preva-
lent in adulthood (10). Adult autoimmune diabetic patients
who are initially noninsulin requiring have latent autoim-
mune diabetes of adults (LADA), which is latent because
without testing for diabetes-associated autoantibodies pa-
tients masquerade clinically as having type 2 diabetes (5).
Other acronyms include slowly progressing insulin-depen-
dent diabetes (SPIDM) or type 1.5 diabetes. Clinicians, in
reality, still use their clinical nose to identify type 1a
diabetes without routinely checking for autoantibodies,
e.g., those for GAD (GADA). But, in maintaining a clinical
rather than an immunogenetic deﬁnition, something is
lost. It follows that the best way to identify autoimmune
diabetes is to assess diabetes-associated autoantibod-
ies, which represent the only relevant categorical trait
(3,4,5,10).
Although there is no evidence that autoantibodies cause
autoimmune diabetes, they share guilt by association. It
follows that: 1) autoantibodies predict autoimmune diabe-
tes irrespective of the age at which they are detected and
2) the antigen could be used for immunomodulation
therapy to alter the disease process. In this issue of
Diabetes, Lundgren et al. report ﬁrm evidence of the
former, allied to recent evidence of the latter (11). Lun-
dgren et al. conﬁrm and extend an earlier study by
showing that GADA, in a large cohort (initially 4,976
subjects were screened) of adult nondiabetic relatives of
type 2 diabetic patients, are signiﬁcant predictors of
diabetes (12). A subgroup of this cohort was followed for
8 years: 252 subjects with GADA and 2,511 subjects
without GADA. If GADA truly predicted diabetes, then
every nondiseased subject with the autoantibody would
eventually develop the disease (high positive predictive
value); however, that value, albeit highly signiﬁcant, was
only 14%. Because this cohort was enriched for GADA
positivity, even that predictive ﬁgure is exaggerated. Nev-
ertheless, several additional factors could have increased
the predictive power. First, limited speciﬁcity of the GADA
assay means that 50 patients had false-positive GADA.
Given such a large cohort, the assay speciﬁcity in recent
years fell to 91%. Repeat testing and testing for multiple
antibodies would have limited false positivity. Indeed, the
predictive power was increased in those who sero-con-
verted, or had high titer GADA. Second, addition of genetic
and metabolic biomarkers, the latter tested prospectively,
would increase predictive power similar to that for chil-
dren at risk (8,13). Of note, many individuals with diabe-
tes-associated autoantibodies do not develop diabetes,
especially when identiﬁed at an older age. In this case,
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relatives of type 1 diabetic patients in whom older age is
also associated with lower risk of progression to diabetes
(14). Further, in line with the proposal that adult-onset
autoimmune diabetes is usually noninsulin requiring, all
but 3 of 36 patients who developed diabetes had a non–
insulin-dependent phenotype 1 year postdiagnosis, i.e.,
they had LADA (11).
The purpose of prediction is prevention. Given that the
predictive power of GADA for diabetes in children now
extends to adults, albeit less impressively, can we prevent
autoimmune diabetes? Certainly, we can modify the disease
process in established diabetes, as illustrated by recent
studies using alum-formulated GAD. Two injections of GAD,
given 30 days apart to GADA-positive childhood-onset and
adult-onset autoimmune diabetic patients, affected serum
C-peptide levels after 2 and 5 years, respectively (15,16). It
was no less remarkable that the effect was modest than that
there was any effect. Alum-formulated GAD, among other
approaches, is now to be given in the pre-diabetic period,
when we anticipate it would have a substantially greater
impact. There was a time when predicting autoimmune
diabetes was beyond our imagination. However, the change
in disease deﬁnition, in association with the identiﬁcation of
disease-associated autoantibodies, has brought diabetes pre-
diction within our grasp. For the perplexed, clarity has come
from complexity and, with it, the real potential of disease
prevention.
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FIG. 1. The spectrum of autoimmune diabetes extends across all ages and varies with age at diagnosis. Older patients are more likely to have
appreciable C-peptide but less likely to have high-risk MHC genes, have multiple autoantibodies, and require insulin treatment. T1DM, type 1
diabetes.
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